MEETINGS - Better co-ordinating US public health agencies, in order to help speed the development of drugs, biologics and medical devices (US) November 2004:
This article was originally published in Clinica
Executive Summary
The US Health and Human Services (HHS) department has scheduled a public meeting for November 15 on Better co-ordinating US public health agencies, in order to help speed the development of drugs, biologics and medical devices. The information will be used by a high-level HHS taskforce that is currently preparing a report on the subject, which must be released by the end of 2004. The meeting will take place at HHS headquarters in Washington. For registration details, contact: Nancy Stanisic at the FDA: [email protected] or by fax: +1 301 443 9718.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.